seriously disabling, running a relapsing/remitting course which eventually becomes progressive (secondary proSeveral experimental autoimmune diseases (AID), gressive MS). In about 10-20% of cases it has a continuincluding allergic encephalomyelitis, ie the multiple ously progressive course from onset (primary progressive sclerosis (MS) model, respond to TBI and chemotherapy MS), which is slow or rapid, or even fulminant with shortfollowed by BMT. Remissions of AID may also occur ened survival. 2 There is strong evidence supporting an in patients with concomitant malignancies treated with immunopathogenic basis for the disease which could, thereallogeneic or autologous BMT. These observations have fore, be regarded as an autoimmune process directed at one emphasized the possibility of treating AID with highor other of the structural components of myelin. 3 Treatment dose therapy and haematopoietic stem cell transplaninvolves anti-inflammatory, immunosuppressive, and tation (HSCT). In a phase I/II pilot study, 15 patients immunomodulating agents, 4,5 some of which are active in with progressive MS were treated with BEAM followed managing relapses or preventing them, but none is curative.
improvement, but also exacerbation of MS have been explanation of the protocol was given to the eligible patients and to their family members. reported. 25 Allogeneic HSCT for AID would reasonably appear to be more efficacious than autologous transplants in mainStem cell mobilization taining immunological remission. However, this yet unknown advantage may not outweigh the increased sysCyclophosphamide (CY) 4 g/m 2 was given for stem cell temic complication rate of GVHD and related morbidity.
mobilization, followed by daily s.c. injections of G-CSF Therefore, if transplantation is used to treat AID, autolog-(lenograstim, eight patients) or GM-CSF (seven patients) ous HSCT would possibly be, at present, a safer alternative.
at 5 g/kg bw, commencing 1 day after CY infusion.
Patients were planned to undergo at least two leukaphereses by means of a Fenwall CS3000-Plus cell separator (Baxter,
Patients and methods
Fenwal Division, Deerfield, IL, USA), starting when neutrophils reached 10 9 /l. The minimum number of CD34
+
Study design cells to be collected for transplantation was set at 4 × 10 6 /kg bw. As no monoclonal antibodies were available, ex vivo The trial was approved by two institutional review commit-T cell depletion was not performed. tees. It was designed as a phase I/II pilot study, testing the protocol in 15 patients with advanced and active disease, aged below 55, who would be followed-up for at least 2
Transplantation procedure years. Target criteria were treatment-related toxicity, possible aggravation of neurologic status, improvement in dis-
The time interval from stem cell harvest to transplantation ability, and relapse after improvement. Enrollment of was 16-52 days (median, 33). The BEAM regimen was patients took place from April 1995 to April 1996. For ethichosen for conditioning and was used at full dose, as in cal reasons only two patients were treated at first and it lymphomas: BCNU 300 mg/m 2 on day −6, etoposide was only after 4 months that more patients were entered 200 mg/m 2 and cytosine-arabinoside 200 mg/m 2 on days −5 into the study. By that time, the results in these two patients to −2, and melphalan 140 mg/m 2 on day −1. On day 0, the appeared very encouraging in terms of acceptable toxicity stem cells were thawed and infused. On days +1 and +2, and improvement in disability.
rabbit ATG (thymoglobulin, Merieux, Lyon, France) at 2.5 mg/kg bw/day was given to the first eight patients, as a sort of in vivo lymphocyte depletion, but the dose was Patients considered low and was doubled (5 mg/kg/day) in the next The 15 patients (eight male, seven female) had definite MS seven patients. G-CSF (lenograstim) was administered at according to the Poser criteria 29 for a time period of 2-28 10 g/kg bw i.v. to all patients from day 0 until absolute years (median, 10). The median age at presentation was neutrophil counts exceeded 1.5 × 10 9 /l for 3 consecutive 37 years (range, 24-54). They were all judged to be in a days. IVIG (Sandoglobulin; Sandoz, Basle, Switzerland) at progressive phase of MS (pMS) for a median of 6 years 0.5 g/kg bw was given as supportive treatment on days −7, (range, 2-17) and had evidence of clinical deterioration of +8, +23, and +38. Oral ciprofloxacin (1 g) fluconazole at least 1.0 point on the Kurtzke Expanded Disability Status (400 mg) and acyclovir (15 mg/kg bw) were given daily Scale (EDSS) 30 over the preceding 12 months. They were as infection prophylaxis. Patients were isolated, but not in also severely disabled, with a median EDSS of 6.0 (range, laminar air flow systems, from the day of admission, ie 1 5.0-7.5) at entry. Median score on the Scripps Neurologic day before starting the conditioning, to the day of disRating Scale (SNRS) 31 was accordingly low, 42 (range, 33-charge. Nursing prophylactic measures were similar to 62). The patients had characteristic abnormalities on magthose taken for patients undergoing transplantation for netic resonance imaging (MRI) scans and in one, brain lymphomas. lesions enhanced with gadolinium-DTPA at enrollment.
The progressive phase of MS was primary in eight patients and secondary in seven, with median durations of Toxicity and haematologic evaluation 8 (range, 2-17) and 6 years (range, 3-8) respectively. Patients had previously received a variety of conventional Adverse experiences were recorded according to the WHO grading system. Special attention was given to the nervous therapies with little or no effect on disease progression and disability. These included soluble methylprednisolone pulsystem during stem cell mobilization and in the immediate post-transplant period, in order to detect toxicities in the ses (14 cases), occasional low-dose prednisolone orally (six), azathioprine (five), mitoxantrone (one), beta-IFN form of aggravation of existing symptoms or the appearance of new ones. After discharge from hospital, follow-(two), and i.v. immunoglobulin (IVIG, two cases). To be eligible for the trial, patients were required to have had up was continued on an outpatient basis until days +40 to +50. Patients were then re-examined at the end of the 3rd no medical illness precluding transplantation and no mental dysfunction precluding the ability to give informed consent. month post-HSCT and every 3 months thereafter, unless an earlier incident required management or hospitalization. All patients were negative for hepatitis B virus (HBV) antigens and for antibodies to the hepatitis C virus. Five Blood lymphocyte phenotype analyses were performed before stem cell mobilization, before conditioning for transpatients who had evidence of past HBV infection (antibodies to HBV) were included in the study. Detailed plantation, and every 3 months after HSCT.
Neurologic evaluation
Two scoring systems were used to assess neurologic status, the Kurtzke EDSS 30 and the Scripps NRS. 31 On the EDSS, normal examination is scored as 0 and death as 10. Patient scores at presentation ranged from 5 to 7.5, indicating impairment of daily activities and degrees of disability varying between inability to walk (without aid) further than 200 metres and restriction to a wheelchair. On the Scripps scale, a score of 100 points represents maximum efficiency. Assessments were made by two neurologists working independently whose rating scores were averaged. Evaluations were done at entry, after mobilization of peripheral blood stem cells, ie before conditioning for HSCT, 1 and 3 months after stem cell infusion, and at 3-month intervals thereafter. Worsening and relapse after improvement were defined as a gain of 1.0 or more EDSS points or a loss of 10 or more SNRS points when scores were compared to the baseline or to the latest assessment scores, respectively. Smaller or no changes on the scales were regarded as indicating stabilization of disease status. Improvement in disability was indicated by reduction of EDSS of 1.0 or more points, or a gain of at least 10 SNRS points.
Serial MRIs were performed along with neurologic clinical assessments. Other criteria included recording of 
Results

Stem cell harvest and haematologic recovery after infusion
The median number of CD34 + cells collected for reinfusion was 10 × 10 6 /kg bw (range, 4.6-19 × 10 6 /kg) and the median number of CD3 + cells was 60 × 10 6 /kg bw (range, 16-270 × 10 6 /kg). GM-CSF and G-CSF were equally effective in mobilizing CD34 + cells. ANC reached 0.5 × 10 9 /l between days +8 and +11 (median, day +10) and platelet counts reached 50 × 10 9 /l between days +8 and +15 (median, day +13). The median number of days spent in hospital for transplantation was 26 (range, 19-36 days). As expected, cell phenotype analysis showed a profound fall 46 ± 5.6% (s.d.) at entry to a nadir of 15.1 ± 8.4% at 3 months post-HSCT (P Ͻ 0.001, paired t-test) and remained very low over the next 12 months. In contrast, the mean Toxicity of stem cell mobilization value of CD8 + cells rose from 23.6 ± 5.9% at entry to 50.5 ± 13.2% at 3 months (P Ͻ 0.001); from this peak, No major complications occurred during the cytopenic period following high-dose CY except for polymicrobial bacvalues declined gradually in the course of time but remained above the corresponding mean CD4
+ values teremia (grade 3). Eight patients had no adverse manifestations; seven had 9 episodes of infection: 7 cases of fever ( Figure 1 ). Small, but significant, changes in CD4
+ and CD8
+ cell counts were also seen after stem cell mobiliz-(FUO) (grade 2), a urinary tract infection (UTI) due to Chromobacterium violaceum (grade 1, minor), and a case ation, apparently caused by the high dose of CY.
However, these were transient (1-2 days) and mild. On day +30, when the first post-transplant assessment was made, no patient was found to have increased his EDSS score by 1 point, or to have decreased his SNRS score. An increase of 0.5 EDSS points was noted in three cases, while the rest of the patients had stable or improved scores. On SNRS, all scores were improved.
After discharge from hospital, three patients needed brief re-hospitalization (2-10 days) between days +20 and +80 for treatment of FUO or documented infections (bacteremia, sinusitis). Despite persistent low blood CD4 + cell counts, late infections (beyond day +100) did not occur, apart from one case of cystitis in a patient with known recurrent UTIS dating from the pre-transplant period. No patient has to date been re-admitted to hospital for a late disorder subsequent to the transplant procedure.
Improvement in disability
The first patient underwent HSCT median follow-up time of the whole group is 6 months. in Tables 2 and 3 and are also depicted in Figures 2 and 3. EDSS scores declined gradually with time while SNRS scores increased, indicating neurological improvement. A of polymicrobial bacteremia, with Streptococcus viridans, Enterococcus faecalis, and Candida albicans recovered two-way analysis of variance performed at 6 months showed that the mean values of patient scores given at the from blood culture. Grade 1 oral mucositis was seen in 3 patients; transient, grade 1, liver toxicity was detected in 1 scheduled assessments showed significant changes during this time period on both scales (P Ͻ 0.01 and P Ͻ 0.001, patient (elevation of transaminases). One patient developed an allergic reaction soon after CY infusion (bronchospasm, respectively). Paired t-test analyses of the mean differences of individual scores from corresponding baseline scores grade 3). Moderate (grade 2) allergic reactions the 'fever with drug' type occurred in two patients receiving GMalso showed significant changes (Table 2 and 3) , which were more prominent on the SNRS as it is more sensitive CSF. One other patient on GM-CSF developed fever with hypotension (grade 4 toxicity) necessitating a switch to Gand not based so much on walking ability. On the EDSS, one patient showed improvement after CSF. Apart from these allergic manifestations with GM-CSF, there were no other differences between GM-CSF and CY. After HSCT, six improvements were detected at the 1st-month assessment (40%, Table 2 ). Two of these six G-CSF, which was very well tolerated. Regarding neurotoxicity, no toxic signs were noted. Moreover, one patient patients were found to have further improved at 3 months and one patient continued to improve at 9 and 15 months improved his EDSS score considerably, from 5 to 3.5, and five patients improved their SNRS scores by 11 to 18 post-HSCT. This patient had a spectacular course, with an EDSS score of 5 at presentation and only 2 at 18 months. points.
One late improvement was also seen in a patient who lost 1 EDSS point at 6 months. In all, seven patients improved.
Transplant-related toxicity
More meaningful changes, ie loss of 1.5 or more EDSS points, were detected in four of the seven patients: one No patient died as a result of protocol therapy. Table 1 shows all complications observed during the immediate improved by 3, one by 2.5, one by 2, and one by 1.5 points during the total follow-up period. The patient with the post-transplant period. Allergy and infections were problematic. Fourteen of the 15 patients developed allergic reacgadolinium-enhancing brain lesions on MRI improved by 1.5 points at 3 months. Patients who did not respond on tions, mostly to ATG, severe enough (anaphylaxis) in two patients to preclude administration of the entire dose of the EDSS (8 of 15) have remained stable to date, 6 to 12 months (median, 6) post-HSCT, except for one, who gained ATG. To prevent anaphylactic phenomena, soluble methylprednisolone was subsequently administered on a regular 1 EDSS point at 6 months. The mean EDSS change (increase) in non-responding cases was 0.11 ± 0.19 at 6 basis, at 0.25 g twice daily for 2 days, along with the ATG. Infectious episodes occurred in 13 patients, bacteremia months. No factors were found to be significantly related to being the most frequent ( ease duration (primary pMS) before HSCT. None of the increases were noted in four patients. There was no worsening on this scale. differences, however, were statistically significant.
On the SNRS, more obvious changes were seen (Table 3) . Scores were found to have already improved Relapses after stem cell mobilization in five patients (due to CY) and also later, at 1, 3, and 6 months, in five, four, and one more No relapses have been detected on the EDSS and, improvements have been durable for 1+ to 18+ months (median, patient, respectively. By 6 months, all patients gained 10 points. Five patients increased their already improved 8). However, on the SNRS, two patients relapsed at 3 and 9 months post-HSCT, after having improved for 2 and 5 scores further at 3 months and late improvements were also seen, at 6 and 12 months (two and one patient, months, respectively. One of these had received a minimal dose of ATG because he developed anaphylactic shock at respectively). Considerable (around 30-40 SNRS points) infusion. Nevertheless, the SNRS scores of these patients patients before HSCT but they had all declined on the EDSS by at least 1 point over the preceding year, with 11 of them have remained above (better than) their respective baseline scores. The rest of the patients (13 of 15) have maintained having evidence of very recent deterioration before HSCT. In experimental BMT, non marrow-ablative doses of TBI their improved SNRS scores for 1+ to 18+ months (median, 5). Moreover, we found no difference, in terms of response are less effective than high doses in preventing spontaneous relapses of EAE. 17 In patients with AID, the most approprior relapse, between the two ATG doses administered (5 mg/kg bw and 10 mg/kg bw).
ate conditioning regimen is unknown. Relatively less myelotoxic regimens, eg high-dose CY alone or 2-chlorodeoxyadenosine, are less immunotoxic than TBI or high-dose busulphan (Bu) 35 which, additionally, can reach and destroy Discussion effector lymphocytes residing in the CNS, a possibly important event for disease remission. 36 However, TBI has The main objective of this study was to assess the feasibility and toxicity of HSCT in the treatment of MS. We also been reported to aggravate neurological symptoms in rats 17, 21 and high-dose Bu may be associated with VOD and attempted to obtain some indications of the clinical efficacy of HSCT on this inexorably crippling disease in which, neurotoxicity. 35 BEAM, which seems to have worked in the trial so far, can be argued to be less immunosuppressive or sometimes, even halting progression could be regarded as a positive treatment result (stabilization). Our results show lymphotoxic than BuCy and may, therefore, not be sufficient to prevent relapse of autoimmunity. However, it is much that peripheral blood HSCT can be used with relative safety to patients with pMS without causing exacerbations of the less toxic. It is very myelotoxic and lymphotoxic, and designed for use especially in autologous HSCT in lymdisease. Some evidence is also provided that, in a number of patients, this kind of therapy can suppress disease prophomas. It has rarely been used in allogeneic transplants.
37
It incorporates drugs that are not neurotoxic at the doses gression and reduce disability, even in those with longstanding disease. Moreover, it seems that some 'remissions' used, 38 it can cross the blood-brain barrier (BCNU, high-dose melphalan, high-dose cytosine-arabinoside) may be sustainable, as in the two of our patients who have completed a follow-up of at least 15 months. and is immunosuppressive (BCNU and high-dose melphalan). 37,39-41 To avoid anesthesia and for faster recovery When designing the protocol, important issues came into question, namely the choice of patients, the choice of highwe chose to use peripheral grafts, although the high numbers of re-infused lymphocytes may cause disease recurrence, dose therapy, the kind of graft, and the means for an objective evaluation of results. For ethical reasons, only patients just as allogeneic grafts from donors with AID can transfer the disease to recipients. [42] [43] [44] To deplete lymphocytes in with advanced disease were eligible, somewhat unrewarding material, as these patients may be more susceptible to the vivo, ATG was administered after stem cell infusion but it proved to be relatively problematic because of allergic debilitating consequences of HSCT 32 or they may have much gliosis in the CNS. Also, since the pattern of deterioreactions. Of the two patients who could not receive ATG, one relapsed (on the SNRS) but the other has maintained ration cannot be easily identified in pMS, 2,33 before HSCT, one has to consider, whether the disease is currently active an improved SNRS score for 6+ months. In contrast to all five cases described by Euler et al, 26 who relapsed after or whether it is in a phase of slow progression or of spontaneous stabilization. Progression of disability over the prereceiving unmanipulated stem cell grafts for AID, we had only two relapses. ATG may, therefore, be of benefit in the vious year 5,7-9 and serial gadolinium-enhanced brain MRI scans 34 have been used as criteria for patient selection in setting of autologous HSCT with unmanipulated peripheral blood grafts. However, our patients' median follow-up time MS trials. Serial MRI scans were not performed in our is still short and longer surveillance is needed. Nevertheless, on the EDSS. Also, there was no correlation between reinfused CD3
+ cells and response (data not the question of the usefulness of other, possibly more effective, methods of lymphocyte depletion (positive CD34 cellshown), either because the EDSS is not sufficiently sensitive to detect minor changes or because other mechanisms are selection, negative T cell-depletion) has not yet been settled.
It would suffice to use only CSF for stem cell mobilizalso implicated in disease improvement. It will be interesting to see whether these improvements will pertain when ation. However, by adding CY at 4 g/m 2 one may gain a first impression of disease sensitivity to high-dose therapy, CD4 + lymphocytes have resumed their normal blood levels. The impact of autologous HSCT on long-term outcome while lower doses of CY (eg 2 g/m 2 ) may not yield improvements. 7 The two CSFs used were administered in a will determine its utility. If improvements are sustained in the future, it will be tempting to conclude that autoreactive randomized manner and yielded similar CD34 + cell counts. However, G-CSF was better than GM-CSF, which caused cells have been eradicated and that tolerance has been acquired through induction of unresponsiveness to tissue allergic phenomena, and is, therefore, preferable for mobilization and acceleration of neutrophil recovery. Infectionsantigens presented to newly emerging T lymphocytes. 18 At present it seems that HSCT may be clinically worthwhile some significant (bacteremia, fungemia) -were frequent in the early post-infusion period, but late ones, despite persistin pMS. The procedure, however, does have a certain mortality risk, probably below 5%, and the results of this study ent immunosuppression, have not as yet occurred. Some mild, transient neurotoxicity did occur after stem cell require confirmation especially as other therapies also claim to be of benefit in pMS. 10, 11, 48, 49 Issues of cost-effectiveness, infusion. Probable causes were the drugs used for the conditioning, infection, 32 and possibly the re-infused lymphoearly mortality, and, also, of late effects including secondary cancer 50 will have to be carefully considered, before (and cytes. The worsening detected in one patient at 6 months can easily be ascribed to the disease, but the possibility that if) prospective, comparative trials are to be undertaken. HSCT had a detrimental effect on his neurologic status should be considered. Nevertheless, the procedure was, in general, well tolerated by the patients, without the need for References long hospitalization.
MS is one of the most difficult diseases in which to judge 
